Production (Stage)
Universal Ibogaine Inc.
IBO.V
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.70% | -40.11% | -33.96% | -2.88% | 25.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.70% | -40.11% | -33.96% | -2.88% | 25.08% |
| Cost of Revenue | -5.17% | -17.43% | -4.56% | 27.20% | 24.44% |
| Gross Profit | 177.98% | -93.75% | -107.66% | -52.13% | 28.23% |
| SG&A Expenses | -59.89% | -39.82% | -31.72% | -79.36% | 6.17% |
| Depreciation & Amortization | -4.55% | 3.47% | -4.54% | 7.89% | 11.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.34% | -23.30% | -9.70% | 11.49% | 14.34% |
| Operating Income | 93.93% | -29.83% | -86.43% | -276.32% | -3.39% |
| Income Before Tax | 92.67% | -30.13% | -65.84% | -175.00% | -76.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.67% | -30.13% | -65.84% | -175.00% | -76.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.67% | -30.13% | -65.84% | -175.00% | -76.87% |
| EBIT | 93.93% | -29.83% | -86.43% | -276.32% | -3.39% |
| EBITDA | 114.27% | -50.45% | -182.53% | -134.11% | -1.84% |
| EPS Basic | 90.91% | 22.22% | 0.00% | -90.91% | -15.79% |
| Normalized Basic EPS | 87.50% | 20.00% | 0.00% | -100.00% | 33.33% |
| EPS Diluted | 90.91% | 22.22% | 0.00% | -163.64% | -15.79% |
| Normalized Diluted EPS | 87.50% | 20.00% | 0.00% | -100.00% | 33.33% |
| Average Basic Shares Outstanding | 8.49% | 60.91% | 60.93% | 37.25% | 48.54% |
| Average Diluted Shares Outstanding | 8.49% | 60.91% | 60.93% | 37.25% | 48.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |